NURS617 EXAM 1 Actual Exam 2026/2027 Complete
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS (Questions 1-15)
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin. The NP understands that
warfarin's anticoagulant effect is monitored using which laboratory value, and what is the
therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0 [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to monitor warfarin.
Q2: A patient taking carbamazepine for seizures is started on oral contraceptives. The NP
recognizes that contraceptive efficacy may be reduced due to which pharmacokinetic
mechanism?
A. Decreased absorption of the contraceptive
B. Increased metabolism via CYP450 enzyme induction [CORRECT]
C. Decreased renal excretion of the contraceptive
D. Increased protein binding of the contraceptive
Correct Answer: B
Rationale: Carbamazepine is a potent CYP450 enzyme inducer (specifically CYP3A4) that
increases the metabolism of oral contraceptives, reducing their efficacy and increasing risk of
unintended pregnancy (B). Patients should be counseled to use alternative contraception
methods. Options A, C, and D do not represent the primary mechanism of this interaction.
,Q3: A 45-year-old patient with chronic pain is prescribed codeine for post-operative pain
management. The patient reports minimal pain relief. Genetic testing reveals the patient is a
CYP2D6 poor metabolizer. What is the pharmacological explanation for this therapeutic failure?
A. Codeine is a prodrug requiring CYP2D6 conversion to morphine for analgesic effect
[CORRECT]
B. CYP2D6 poor metabolizers rapidly clear codeine from the body
C. Poor metabolizers have increased sensitivity to codeine's side effects
D. Codeine requires CYP3A4 activation, which is deficient in this patient
Correct Answer: A
Rationale: Codeine is a prodrug that requires metabolism by CYP2D6 to convert approximately
10% of the dose to morphine, which provides the analgesic effect (A). CYP2D6 poor
metabolizers cannot effectively convert codeine to morphine, resulting in inadequate pain relief.
Alternative analgesics should be selected for these patients.
Q4: A patient with liver cirrhosis is prescribed a medication with high first-pass metabolism. The
NP anticipates which pharmacokinetic change in this patient?
A. Decreased bioavailability of the drug
B. Increased bioavailability of the drug [CORRECT]
C. Increased renal clearance of the drug
D. Decreased volume of distribution
Correct Answer: B
Rationale: In liver cirrhosis, impaired hepatic function reduces first-pass metabolism, resulting
in increased bioavailability of drugs that normally undergo extensive hepatic extraction (B). This
may lead to higher plasma concentrations and increased risk of toxicity, requiring dose
adjustments. Options A, C, and D are incorrect based on pathophysiology.
Q5: A 72-year-old patient with hypoalbuminemia is prescribed warfarin. The NP understands
that the patient's decreased albumin levels will result in which pharmacokinetic alteration?
A. Increased free (unbound) warfarin and increased risk of bleeding [CORRECT]
B. Decreased free warfarin and decreased anticoagulant effect
C. Increased metabolism of warfarin
D. Decreased volume of distribution
Correct Answer: A
Rationale: Warfarin is highly protein-bound (99%) primarily to albumin. In hypoalbuminemia,
less drug is bound to protein, resulting in increased free (pharmacologically active) warfarin
, concentrations and increased risk of bleeding despite normal total warfarin levels (A). The NP
should monitor closely and consider lower initial doses.
Q6: A patient with G6PD deficiency develops hemolytic anemia after receiving primaquine. This
adverse reaction represents which type of pharmacogenomic effect?
A. Pharmacokinetic variation in drug metabolism
B. Pharmacodynamic variation in drug sensitivity [CORRECT]
C. Idiosyncratic drug reaction unrelated to genetics
D. Drug-drug interaction
Correct Answer: B
Rationale: G6PD deficiency is a pharmacodynamic variation where patients have reduced
ability to maintain glutathione in reduced form, leading to hemolytic anemia when exposed to
oxidative stressors like primaquine (B). This represents altered pharmacodynamic response
rather than altered pharmacokinetics. Screening for G6PD deficiency is essential before
prescribing primaquine.
Q7: A patient on multiple medications presents with elevated drug concentrations and toxicity.
The NP identifies that grapefruit juice consumption is the cause. Which CYP450 enzyme is
primarily inhibited by grapefruit juice?
A. CYP2D6
B. CYP2C19
C. CYP3A4 [CORRECT]
D. CYP1A2
Correct Answer: C
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal and
hepatic CYP3A4, significantly increasing bioavailability of CYP3A4 substrates such as statins,
calcium channel blockers, and immunosuppressants (C). This interaction can persist for 24-72
hours after grapefruit juice consumption.
Q8: A patient receives two drugs that both lower blood pressure through different mechanisms,
resulting in a blood pressure reduction greater than the sum of each drug's individual effect. This
represents which type of drug interaction?
A. Additive effect
B. Synergistic effect [CORRECT]
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS (Questions 1-15)
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin. The NP understands that
warfarin's anticoagulant effect is monitored using which laboratory value, and what is the
therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0 [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to monitor warfarin.
Q2: A patient taking carbamazepine for seizures is started on oral contraceptives. The NP
recognizes that contraceptive efficacy may be reduced due to which pharmacokinetic
mechanism?
A. Decreased absorption of the contraceptive
B. Increased metabolism via CYP450 enzyme induction [CORRECT]
C. Decreased renal excretion of the contraceptive
D. Increased protein binding of the contraceptive
Correct Answer: B
Rationale: Carbamazepine is a potent CYP450 enzyme inducer (specifically CYP3A4) that
increases the metabolism of oral contraceptives, reducing their efficacy and increasing risk of
unintended pregnancy (B). Patients should be counseled to use alternative contraception
methods. Options A, C, and D do not represent the primary mechanism of this interaction.
,Q3: A 45-year-old patient with chronic pain is prescribed codeine for post-operative pain
management. The patient reports minimal pain relief. Genetic testing reveals the patient is a
CYP2D6 poor metabolizer. What is the pharmacological explanation for this therapeutic failure?
A. Codeine is a prodrug requiring CYP2D6 conversion to morphine for analgesic effect
[CORRECT]
B. CYP2D6 poor metabolizers rapidly clear codeine from the body
C. Poor metabolizers have increased sensitivity to codeine's side effects
D. Codeine requires CYP3A4 activation, which is deficient in this patient
Correct Answer: A
Rationale: Codeine is a prodrug that requires metabolism by CYP2D6 to convert approximately
10% of the dose to morphine, which provides the analgesic effect (A). CYP2D6 poor
metabolizers cannot effectively convert codeine to morphine, resulting in inadequate pain relief.
Alternative analgesics should be selected for these patients.
Q4: A patient with liver cirrhosis is prescribed a medication with high first-pass metabolism. The
NP anticipates which pharmacokinetic change in this patient?
A. Decreased bioavailability of the drug
B. Increased bioavailability of the drug [CORRECT]
C. Increased renal clearance of the drug
D. Decreased volume of distribution
Correct Answer: B
Rationale: In liver cirrhosis, impaired hepatic function reduces first-pass metabolism, resulting
in increased bioavailability of drugs that normally undergo extensive hepatic extraction (B). This
may lead to higher plasma concentrations and increased risk of toxicity, requiring dose
adjustments. Options A, C, and D are incorrect based on pathophysiology.
Q5: A 72-year-old patient with hypoalbuminemia is prescribed warfarin. The NP understands
that the patient's decreased albumin levels will result in which pharmacokinetic alteration?
A. Increased free (unbound) warfarin and increased risk of bleeding [CORRECT]
B. Decreased free warfarin and decreased anticoagulant effect
C. Increased metabolism of warfarin
D. Decreased volume of distribution
Correct Answer: A
Rationale: Warfarin is highly protein-bound (99%) primarily to albumin. In hypoalbuminemia,
less drug is bound to protein, resulting in increased free (pharmacologically active) warfarin
, concentrations and increased risk of bleeding despite normal total warfarin levels (A). The NP
should monitor closely and consider lower initial doses.
Q6: A patient with G6PD deficiency develops hemolytic anemia after receiving primaquine. This
adverse reaction represents which type of pharmacogenomic effect?
A. Pharmacokinetic variation in drug metabolism
B. Pharmacodynamic variation in drug sensitivity [CORRECT]
C. Idiosyncratic drug reaction unrelated to genetics
D. Drug-drug interaction
Correct Answer: B
Rationale: G6PD deficiency is a pharmacodynamic variation where patients have reduced
ability to maintain glutathione in reduced form, leading to hemolytic anemia when exposed to
oxidative stressors like primaquine (B). This represents altered pharmacodynamic response
rather than altered pharmacokinetics. Screening for G6PD deficiency is essential before
prescribing primaquine.
Q7: A patient on multiple medications presents with elevated drug concentrations and toxicity.
The NP identifies that grapefruit juice consumption is the cause. Which CYP450 enzyme is
primarily inhibited by grapefruit juice?
A. CYP2D6
B. CYP2C19
C. CYP3A4 [CORRECT]
D. CYP1A2
Correct Answer: C
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal and
hepatic CYP3A4, significantly increasing bioavailability of CYP3A4 substrates such as statins,
calcium channel blockers, and immunosuppressants (C). This interaction can persist for 24-72
hours after grapefruit juice consumption.
Q8: A patient receives two drugs that both lower blood pressure through different mechanisms,
resulting in a blood pressure reduction greater than the sum of each drug's individual effect. This
represents which type of drug interaction?
A. Additive effect
B. Synergistic effect [CORRECT]
